XML 64 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration Agreements (Details) - USD ($)
1 Months Ended 12 Months Ended
Mar. 31, 2018
Jul. 31, 2017
Sep. 30, 2015
Mar. 31, 2014
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Gain on termination of collaboration agreement $ 4,398,000       $ 4,398,000        
Additional milestone payments or royalties received         0        
Development [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestone payment received               $ 5,000,000  
Health Canada [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestone payment received             $ 8,000,000    
Teva Pharmaceutical [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative development and license agreement revenue recognized         $ 0 $ 59,000      
Teva Canada Limited [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Number of common shares agreed to transfer and assign for cancellation 1,000,000                
Teva Pharmaceuticals International GmbH and Teva Canada Limited [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative development and license agreement termination date Mar. 31, 2018                
Genentech [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Proceeds from upfront fee       $ 1,500,000          
Milestone payment received   $ 250,000 $ 250,000            
Potential Milestone Payments Receivable       $ 1,500,000         $ 613,000,000
Genentech [Member] | Pre-clinical And Clinical Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential Milestone Payments Receivable                 45,500,000
Genentech [Member] | Regulatory Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential Milestone Payments Receivable                 387,500,000
Genentech [Member] | Sales Based Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential Milestone Payments Receivable                 180,000,000
Genentech [Member] | Licensing Agreements [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Proceeds from upfront fee                 10,000,000
Genentech [Member] | GDC-0276 [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Proceeds from upfront fee                 $ 10,000,000